Acorda Therapeutics Inc (NASDAQ:ACOR) major shareholder Scopia Capital Management Lp sold 13,829 shares of the business’s stock in a transaction dated Thursday, September 6th. The shares were sold at an average price of $27.82, for a total value of $384,722.78. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Major shareholders that own 10% or more of a company’s stock are required to disclose their transactions with the SEC.

Scopia Capital Management Lp also recently made the following trade(s):

  • On Tuesday, September 4th, Scopia Capital Management Lp sold 200 shares of Acorda Therapeutics stock. The shares were sold at an average price of $29.00, for a total value of $5,800.00.
  • On Tuesday, August 28th, Scopia Capital Management Lp sold 20,256 shares of Acorda Therapeutics stock. The shares were sold at an average price of $29.41, for a total value of $595,728.96.
  • On Monday, July 23rd, Scopia Capital Management Lp sold 25,000 shares of Acorda Therapeutics stock. The shares were sold at an average price of $28.32, for a total value of $708,000.00.
  • On Wednesday, July 25th, Scopia Capital Management Lp sold 86,551 shares of Acorda Therapeutics stock. The shares were sold at an average price of $28.61, for a total value of $2,476,224.11.
  • On Friday, July 20th, Scopia Capital Management Lp sold 108,740 shares of Acorda Therapeutics stock. The shares were sold at an average price of $29.09, for a total value of $3,163,246.60.
  • On Friday, July 13th, Scopia Capital Management Lp sold 100 shares of Acorda Therapeutics stock. The shares were sold at an average price of $30.00, for a total value of $3,000.00.
  • On Tuesday, July 17th, Scopia Capital Management Lp sold 33,299 shares of Acorda Therapeutics stock. The shares were sold at an average price of $30.04, for a total value of $1,000,301.96.
  • On Tuesday, July 10th, Scopia Capital Management Lp sold 200,354 shares of Acorda Therapeutics stock. The shares were sold at an average price of $30.61, for a total value of $6,132,835.94.
  • On Thursday, July 5th, Scopia Capital Management Lp sold 27,093 shares of Acorda Therapeutics stock. The shares were sold at an average price of $30.10, for a total value of $815,499.30.
  • On Monday, July 2nd, Scopia Capital Management Lp sold 35,889 shares of Acorda Therapeutics stock. The shares were sold at an average price of $30.06, for a total value of $1,078,823.34.

Shares of NASDAQ ACOR opened at $27.55 on Friday. Acorda Therapeutics Inc has a 12 month low of $16.55 and a 12 month high of $36.35. The company has a quick ratio of 3.92, a current ratio of 4.09 and a debt-to-equity ratio of 0.56. The stock has a market cap of $1.32 billion, a PE ratio of 27.52 and a beta of 1.46.

Acorda Therapeutics (NASDAQ:ACOR) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported $1.40 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.50 by $0.90. Acorda Therapeutics had a positive return on equity of 8.19% and a negative net margin of 26.87%. The company had revenue of $153.30 million during the quarter, compared to analyst estimates of $138.63 million. During the same quarter in the previous year, the firm earned $0.29 earnings per share. Acorda Therapeutics’s revenue was up 10.0% on a year-over-year basis. sell-side analysts anticipate that Acorda Therapeutics Inc will post -0.09 EPS for the current year.

Several hedge funds and other institutional investors have recently modified their holdings of ACOR. Millennium Management LLC grew its holdings in shares of Acorda Therapeutics by 269.6% during the first quarter. Millennium Management LLC now owns 734,774 shares of the biopharmaceutical company’s stock worth $17,377,000 after purchasing an additional 535,970 shares in the last quarter. Renaissance Technologies LLC grew its holdings in shares of Acorda Therapeutics by 228.1% during the second quarter. Renaissance Technologies LLC now owns 680,900 shares of the biopharmaceutical company’s stock worth $19,542,000 after purchasing an additional 473,400 shares in the last quarter. Baker BROS. Advisors LP purchased a new position in shares of Acorda Therapeutics during the second quarter worth about $4,968,000. Dimensional Fund Advisors LP grew its holdings in shares of Acorda Therapeutics by 5.7% during the first quarter. Dimensional Fund Advisors LP now owns 3,121,775 shares of the biopharmaceutical company’s stock worth $73,830,000 after purchasing an additional 167,084 shares in the last quarter. Finally, Nexthera Capital LP purchased a new position in shares of Acorda Therapeutics during the second quarter worth about $4,259,000.

ACOR has been the topic of several analyst reports. BidaskClub cut Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 19th. HC Wainwright set a $31.00 price target on Acorda Therapeutics and gave the company a “buy” rating in a research report on Wednesday, May 30th. ValuEngine cut Acorda Therapeutics from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 18th. Zacks Investment Research upgraded Acorda Therapeutics from a “hold” rating to a “buy” rating and set a $33.00 price target on the stock in a research report on Tuesday, July 3rd. Finally, Cowen reiterated a “buy” rating and set a $30.00 price target on shares of Acorda Therapeutics in a research report on Thursday, August 2nd. One investment analyst has rated the stock with a sell rating, nine have given a hold rating and six have issued a buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average target price of $24.69.

About Acorda Therapeutics

Acorda Therapeutics, Inc, a biopharmaceutical company, identifies, develops, and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Qutenza, a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia.

Featured Article: Price to Earnings Ratio (PE) Basics

Insider Buying and Selling by Quarter for Acorda Therapeutics (NASDAQ:ACOR)

Receive News & Ratings for Acorda Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Acorda Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.